A new study conducted in Israel concluded that “medical cannabis (MC) treatment is generally safe for oncology patients and can potentially reduce the burden of associated symptoms with no serious MC-related adverse effects.”
The use of medical cannabis in place of opioids for pain relief in cancerous patients has been primarily driven by the patients’ preferences, rather than via recommendations by the treating doctors. This is mainly due to the lack of large controlled research into the effectiveness of medical cannabis compared to the known effects of opioids. However, despite any lack of positive input from their doctors, people are increasingly opting for medical cannabis as a pain mitigator. This is probably due to two parallel factors. On the one hand, medical cannabis has gained increasing acceptability in the public domain in step with the overall improvement in the public’s attitude towards marijuana. On the other hand, there has been tremendous negative publicity about opioids, which is leading more and more people to reject them as a preferred treatment.Â
Research into medical cannabis in pain relief to date
Research into medical cannabis in pain relief so far has been limited to only five or six randomized controlled trials and just three cohort studies. They primarily investigated the effects of cannabinoids on the relief of chronic pain that was not alleviated by optimized opioid therapy. But for most patients, the most extreme condition is not necessarily relevant. Medical cannabis does have some mild adverse effects from cannabinoids when used in cancer treatment. Still, they are generally well tolerated by patients even when the negative effect is moderate. The most frequent adverse effects are:- Memory impairment
- Drowsiness
- Nausea
- Vomiting
- Dry mouth